G2B BioSolutions ApS: Financial statements 2023
CVR: 42437069
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
G2B BioSolutions ApS (CVR 42437069) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -739,652 and a net result of DKK -1,513,784 compared with DKK -218,552 the year before. Equity in the 2023 report amounted to DKK -1,720,976. The company had 2 employees in the financial year.
- Gross Profit
- DKK -739,652
- Profit/Loss
- DKK -1,513,784
- Equity
- DKK -1,720,976
- Total Assets
- DKK 90,191
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -740 t. | -1.5 mio. | -1.7 mio. | 2 |
| 2022 | - | -171 t. | -219 t. | -207 t. | 1 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
G2B BioSolutions ApS has published its annual report for 2022. Gross profit came to DKK -171,184, and the net result was DKK -218,552.
About G2B BioSolutions ApS
G2B BioSolutions ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Dayanand Suryabhan Jadhav. The company is owned by Dayanand Jadhav Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 44,817 and a net result of DKK 136,864 compared with DKK 370,740 the year before. Equity in the 2025 report amounted to DKK -1,213,372.